To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Aliskiren (INN) is a first in class renin inhibitor co-developed by the Swiss pharmaceutical companies Novartis and Speedel. It was approved by the U.S. Food and Drug Administration in 2007 for the treatment of hypertension. The trade name for aliskiren is Tekturna in the USA, and Rasilez in the UK.
A rare adverse event was allergic swelling of the face, lips or tongue and difficulty breathing, side effects that are common with other drugs for hypertension that act directly on the renin-angiotensin system. 
As with ACE inhibitors, renin inhibitors should not be used in pregnancy, specifically the second and third trimesters, during which they will interfere with fetal kidney development and lead to oligohydramnios.
Aliskiren has not yet been evaluated in patients with significantly impaired renal function.
Minor substrate of CYP3A4:
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Aliskiren". A list of authors is available in Wikipedia.|